Jubilant Pharmova shares are likely to remain in focus after the company reported a mixed set of financial results for the quarter ended June 2026

Jubilant Pharmova shares are likely to remain in focus after the company reported a mixed set of financial results for the quarter ended June 2026. The company’s Q1 net profit declined 45% year-on-year, while revenue increased 17.3%. EBITDA also fell 14.4% during the quarter. For the financial year ended March 2026, the company reported total assets of ₹9,560 crore, including fixed assets of ₹6,713 crore and current assets of ₹1,299 crore. Total liabilities stood at ₹9,560 cror. Share capital stood at ₹131 crore, while reserves and surplus amounted to ₹2,160 crore. During FY26, Jubilant Pharmova generated ₹1,893 crore from operating activities. Investing activities resulted in an outflow of ₹1,084 crore, while financing activities saw an outflow of ₹780 crore. The company reported a net cash flow of ₹28 crore for the year. The company has consistently declared a final dividend of ₹1.20 per share annually from 2022 to 2026. The ex-dividend date for the 2026 final dividend was July 17, 2026. Jubilant Pharmova had announced a 1:1 bonus issue in June 2018 and subsequently carried out a stock split in April 2022, reducing the face value of its shares to ₹2. The company has also scheduled a conference call to discuss its Q1FY27 financial results and recently made other disclosures under SEBI Listing Regulations, including newspaper publications.